While TIGIT and PD-1 combined blockade had a synergistic effect in improving tumor control and survival in mouse models and early clinical trials [12,28], in a B16 mouse model the therapeutic efficacy of PD-1 and TIGIT blockade depended on the presence of NK cells, as NK cell depletion abolished the effect [29]. Here, TIGIT is linked to neoplasm.